Therapeutic gene editing in haematological disorders with CRISPR/Cas9. „British Journal of Haematology”. 185 (5), s. 821–835, June 2019. DOI: 10.1111/bjh.15851. PMID: 30864164. (ang.).
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. 2010. „Blood”. 116 (20), s. 4099–102, 2010. DOI: 10.1182/blood-2010-04-281931. PMID: 20668228. (ang.).
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. „Journal of Clinical Oncology”. 2015 (33), s. 540–9, 2015. DOI: 10.1200/JCO.2014.56.2025. PMID: 25154820. (ang.).
Therapeutic gene editing in haematological disorders with CRISPR/Cas9. „British Journal of Haematology”. 185 (5), s. 821–835, June 2019. DOI: 10.1111/bjh.15851. PMID: 30864164. (ang.).
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. 2010. „Blood”. 116 (20), s. 4099–102, 2010. DOI: 10.1182/blood-2010-04-281931. PMID: 20668228. (ang.).
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. „Journal of Clinical Oncology”. 2015 (33), s. 540–9, 2015. DOI: 10.1200/JCO.2014.56.2025. PMID: 25154820. (ang.).